Home/Filings/4/0001782135-25-000013
4//SEC Filing

Mercier Johanna 4

Accession 0001782135-25-000013

CIK 0000882095other

Filed

Nov 17, 7:00 PM ET

Accepted

Nov 18, 6:51 PM ET

Size

10.5 KB

Accession

0001782135-25-000013

Insider Transaction Report

Form 4
Period: 2025-11-17
Mercier Johanna
Chief Commercial Officer
Transactions
  • Sale

    Common Stock

    2025-11-17$125.83/sh25,524$3,211,560109,669 total
  • Exercise/Conversion

    Non-qualified Stock Option (Right to Buy)

    2025-11-1725,00073,110 total
    Exercise: $66.64Exp: 2029-07-24Common Stock (25,000 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-17$66.64/sh+25,000$1,666,000135,193 total
  • Sale

    Common Stock

    2025-11-17$126.26/sh2,476$312,614107,193 total
Footnotes (4)
  • [F1]The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
  • [F2]Sales prices for the transactions reported here range from $125.23 to $126.20. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  • [F3]Sales prices for the transactions reported here range from $126.23 to $126.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  • [F4]The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Issuer

GILEAD SCIENCES, INC.

CIK 0000882095

Entity typeother

Related Parties

1
  • filerCIK 0001782135

Filing Metadata

Form type
4
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 6:51 PM ET
Size
10.5 KB